InvestorsHub Logo
Followers 0
Posts 253
Boards Moderated 0
Alias Born 03/01/2006

Re: io_io post# 796

Monday, 10/08/2007 12:02:41 PM

Monday, October 08, 2007 12:02:41 PM

Post# of 9772
My bet is that DORB did a poor job in the preparation of their NDA. If the ODAC is any indication, they didn't make a good presentation of the 10-day (post hoc) guarantee period, and the probably didn't have any answer for the differential (and inconsistent between trials) effect in myelos vs. non-myelos.

When you're talking about failing a primary endpoint these unexplained effects give one less confidence that there isn't type1 error in the DORB analysis.

IMO approval/approvable will hinge on how well DORB can defend their data on these two points. In the ODAC they were inadequate.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent SNGX News